|
1
|
Yamamoto S, Kawakami S, Yonese J, Fujii Y,
Urakami S, Masuda H, Numao N, Ishikawa Y, Kohno A and Fukui I:
Long-term oncological outcome and risk stratification in men with
high-risk prostate cancer treated with radical prostatectomy. Jpn J
Clin Oncol. 42:541–547. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Peyromaure EM, Mao K, Sun Y, Xia S, Jiang
N, Zhang S, Wang G, Liu Z and Debré B: A comparative study of
prostate cancer detection and management in China and in France.
Can J Urol. 16:4472–4477. 2009.PubMed/NCBI
|
|
3
|
Walz J, Gallina A, Saad F, Montorsi F,
Perrotte P, Shariat SF, Jeldres C, Graefen M, Bénard F, McCormack
M, et al: A nomogram predicting 10-year life expectancy in
candidates for radical prostatectomy or radiotherapy for prostate
cancer. J Clin Oncol. 25:3576–3581. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hoang DT, Iczkowski KA, Kilari D, See W
and Nevalainen MT: Androgen receptor-dependent and -independent
mechanisms driving prostate cancer progression: Opportunities for
therapeutic targeting from multiple angles. Oncotarget.
8:3724–3745. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nana-Sinkam SP and Croce CM: Clinical
applications for microRNAs in cancer. Clin Pharmacol Ther.
93:98–104. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Farazi TA, Hoell JI, Morozov P and Tuschl
T: MicroRNAs in human cancer. Adv Exp Med Biol. 774:1–20. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Baer C, Claus R and Plass C: Genome-wide
epigenetic regulation of miRNAs in cancer. Cancer Res. 73:473–477.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ebrahimi F, Gopalan V, Smith RA and Lam
AK: miR-126 in human cancers: Clinical roles and current
perspectives. Exp Mol Pathol. 96:98–107. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Feng R, Chen X, Yu Y, Su L, Yu B, Li J,
Cai Q, Yan M, Liu B and Zhu Z: miR-126 functions as a tumour
suppressor in human gastric cancer. Cancer Lett. 298:50–63. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Crawford M, Brawner E, Batte K, Yu L,
Hunter MG, Otterson GA, Nuovo G, Marsh CB and Nana-Sinkam SP:
MicroRNA-126 inhibits invasion in non-small cell lung carcinoma
cell lines. Biochem Biophys Res Commun. 373:607–612. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kumar S, Davra VE, Obr A, Geng KL, Wood T
and Birge R: Crk adaptor protein promotes PD-L1 expression, EMT and
immune evasion in a murine model of triple-negative breast cancer.
Oncoimmunology. 7:e13761552017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tsuda M and Tanaka S: Roles for crk in
cancer metastasis and invasion. Genes Cancer. 3:334–340. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang J, Lan H, Huang X, Liu B and Tong Y:
MicroRNA-126 inhibits tumor cell growth and its expression level
correlates with poor survival in non-small cell lung cancer
patients. PLoS One. 7:e429782012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun X, Liu Z, Yang Z, Xiao L, Wang F, He
Y, Su P, Wang J and Jing B: Association of microRNA-126 expression
with clinicopathological features and the risk of biochemical
recurrence in prostate cancer patients undergoing radical
prostatectomy. Diagn Pathol. 8:2082013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Song L, Xie X, Yu S, Peng F and Peng L:
MicroRNA-126 inhibits proliferation and metastasis by targeting
pik3r2 in prostate cancer. Mol Med Rep. 13:1204–1210. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Duffy MJ, McKiernan E, O'Donovan N and
McGowan PM: Role of ADAMs in cancer formation and progression. Clin
Cancer Res. 15:1140–1144. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Josson S, Anderson CS, Sung SY, Johnstone
PA, Kubo H, Hsieh CL, Arnold R, Gururajan M, Yates C and Chung LW:
Inhibition of ADAM9 expression induces epithelial phenotypic
alterations and sensitizes human prostate cancer cells to radiation
and chemotherapy. Prostate. 71:232–240. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nalla AK, Estes N, Patel J and Rao JS:
N-cadherin mediates angiogenesis by regulating monocyte
chemoattractant protein-1 expression via PI3K/Akt signaling in
prostate cancer cells. Exp Cell Res. 317:2512–2521. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Agostini M, Pucciarelli S, Calore F, Bedin
C, Enzo M and Nitti D: miRNAs in colon and rectal cancer: A
consensus for their true clinical value. Clin Chim Acta.
411:1181–1186. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tian L, Fang YX, Xue JL and Chen JZ: Four
microRNAs promote prostate cell proliferation with regulation of
PTEN and its downstream signals in vitro. PLoS One. 8:e758852013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kopczyńska E: Role of microRNAs in the
resistance of prostate cancer to docetaxel and paclitaxel. Contemp
Oncol (Pozn). 19:423–427. 2015.PubMed/NCBI
|
|
23
|
Nath D, Slocombe PM, Webster A, Stephens
PE, Docherty AJ and Murphy G: Meltrin gamma(ADAM-9) mediates
cellular adhesion through alpha(6)beta(1)integrin, leading to a
marked induction of fibroblast cell motility. J Cell Sci.
113:2319–2328. 2000.PubMed/NCBI
|
|
24
|
Lendeckel U, Kohl J, Arndt M, Carl-McGrath
S, Donat H and Röcken C: Increased expression of ADAM family
members in human breast cancer and breast cancer cell lines. J
Cancer Res Clin Oncol. 131:41–48. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shintani Y, Higashiyama S, Ohta M,
Hirabayashi H, Yamamoto S, Yoshimasu T, Matsuda H and Matsuura N:
Overexpression of ADAM9 in non-small cell lung cancer correlates
with brain metastasis. Cancer Res. 64:4190–4196. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mazzocca A, Coppari R, De Franco R, Cho
JY, Libermann TA, Pinzani M and Toker A: A secreted form of ADAM9
promotes carcinoma invasion through tumor-stromal interactions.
Cancer Res. 65:4728–4738. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim JM, Jeung HC, Rha SY, Yu EJ, Kim TS,
Shin YK, Zhang X, Park KH, Park SW, Chung HC and Powis G: The
effect of disintegrin-metalloproteinase ADAM9 in gastric cancer
progression. Mol Cancer Ther. 13:3074–3085. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fry JL and Toker A: Secreted and
membrane-bound isoforms of protease ADAM9 have opposing effects on
breast cancer cell migration. Cancer Res. 70:8187–8198. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Itabashi H, Maesawa C, Oikawa H, Kotani K,
Sakurai E, Kato K, Komatsu H, Nitta H, Kawamura H, Wakabayashi G
and Masuda T: Angiotensin II and epidermal growth factor receptor
cross-talk mediated by a disintegrin and metalloprotease
accelerates tumor cell proliferation of hepatocellular carcinoma
cell lines. Hepatol Res. 38:601–613. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hirao T, Nanba D, Tanaka M, Ishiguro H,
Kinugasa Y, Doki Y, Yano M, Matsuura N, Monden M and Higashiyama S:
Overexpression of ADAM9 enhances growth factor-mediated recycling
of E-cadherin in human colon cancer cell line HT29 cells. Exp Cell
Res. 312:331–339. 2006.PubMed/NCBI
|
|
31
|
Mahimkar RM, Visaya O, Pollock AS and
Lovett DH: The disintegrin domain of ADAM9: A ligand for multiple
beta1 renal integrins. Biochem J. 385:461–468. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Demirkan BM: The roles of
epithelial-to-mesenchymal transition (EMT) and
mesenchymal-to-epithelial transition (MET) in breast cancer bone
metastasis: Potential targets for prevention and treatment. J Clin
Med. 2:264–282. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xie Y, Liu S, Lu W, Yang Q, Williams KD,
Binhazim AA, Carver BS, Matusik RJ and Chen Z: Slug regulates
E-cadherin repression via p19Arf in prostate tumorigenesis. Mol
Oncol. 8:1355–1364. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cui Y and Yamada S: N-cadherin dependent
collective cell invasion of prostate cancer cells is regulated by
the N-terminus of α-catenin. PLoS One. 8:e550692013. View Article : Google Scholar : PubMed/NCBI
|
